Covidien (COV) Tops Q2 EPS by 1c
Tweet
Share
E-mailGet Alerts COV Hot Sheet
Join SI Premium – FREE
Covidien (NYSE: COV) reported Q2 EPS of $0.96, $0.01 better than the analyst estimate of $0.95. Revenue for the quarter came in at $2.6 billion versus the consensus estimate of $2.61 billion.
For earnings history and earnings-related data on Covidien (COV) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
- LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
- Innovaro (INV) Misses Q2 EPS by 9c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
